

# **BIBLIOGRAPHIE : Substances psychédéliques : Généralités, Épistémologie, Pharmacologie, Neurophysiologie, Psychologie, ...**

***Dr Christian SUEUR, GRECC, mai 2020(nouvelle version)***

Substances psychédéliques : Généralités, Pharmacologie, Neurophysiologie : 1 - 17  
Substances psychédéliques et «psychologie » : 18 - 20

Cf également :

Bibliographie : Thérapies psychédéliques,  
Bibliographie : Substances psychédéliques, culture, chamanisme, spiritualité, religion...  
Bibliographie : Psilocybine,  
Bibliographie : LSD,  
Bibliographie : Ayahuasca,  
Bibliographie : Mescaline et Peyotl,  
Bibliographie : MDMA,  
Bibliographie : Tryptamines  
...

1. ADAY J.S., BLOESCH E.K., DAVOLI C.C. : Beyond LSD : A Broader Psychedelic Zeitgeist during the Early to Mid-20<sup>th</sup> Century, *Journal of Psychoactive Drugs*, 2019, 1-8.  
Doi : 10.1080/02791072.2019.1581961
2. ADAY J.S., BLOESCH E.K., DAVOLI C.C. : Can Psychedelic Drugs Attenuate Age-Related Changes in Cognition and Affect ?, *Journal of Cognitive Enhancement*, 2019.
3. ADAY J.S., MITZKOVITZ C.M., BLOESCH E.K., DAVOLI C.C., DAVIS A.K. : Long-term effects of psychedelic drugs : A systematic review, *Neuroscience and Biobehavioral Reviews*, 2020, 1-8.  
Doi : 10.1016/j.neubiorev.2020.03.017
4. AGHAJANIAN G.K., MAREK G.J. : Serotonin and hallucinogens, *Neuropsychopharmacology*, 1999, 21, (2), 16S–23S.
5. ALLAIN P. : Hallucinogènes et société. Cannabis et peyotl, phénomènes culturels et mondes de l'imaginaire, Paris, Payot, 1973.
6. ALL NATIVE GROUP : Assessment of Potential Long-Term Health Effects on Army Human Test Subjects of Relevant Biological and Chemical Agents, Drugs, Medications and Substances, SUPPORT SERVICES, Literature Review and Analysis, Contract Number W81XWH-14-R-0102, February 29, 2016.  
[www.dtic.mil/cgi-bin/GetTRDoc?Location=U2&docname=GetTRDoc.pdf&ADNumber=W81XWH-14-R-0102](http://www.dtic.mil/cgi-bin/GetTRDoc?Location=U2&docname=GetTRDoc.pdf&ADNumber=W81XWH-14-R-0102)
7. APPEL J.B., WEST W.B., BUGGY J. : LSD, 5-HT (serotonin), and the evolution of a behavioral assay, *Neuroscience and Biobehavioral Reviews*, 2004, 27, 693-701.

8. APUD I. : Pharmacology of Consciousness or Pharmacology of Spirituality ? A Historical Review of Psychedelic Clinical Studies, *The Journal of Transpersonal Psychology*, 2016, 48, (2), 150-167.
9. ARVEILLER J., SUEUR C. : Iatrogénèse et constitution du savoir sur les toxicomanies, *L'Évolution Psychiatrique*, 1989, 54, 2, 333-353.
10. ASERINSKY E., KLEITMANN. : Regularly occurring periods of eye motility, and concomitant phenomena, during sleep, *Science*, 1953, 118, 3062, 273-274.
11. ASHER J : Whatever happened to psychedelic research ?, *APA Monitor on Psychology*, 1975, 6, (10), 4-5.
12. ATASOY S., DONNELLY I., PEARSON J. : Human Brain networks function in connectome-specific harmonic waves, *Nature Communications*, 2016, 7, 1-10.
13. ATASOY S., ROSEMAN L., KAELEN., KRINGELBACH M.L., DECO G., CARHART-HARRIS R.L. : Critical brain dynamics under LSD revealed by connectome-specific harmonic decomposition, *Scientific Reports – Nature*, 2017, 7, 17661.
14. ATASOY S., DECO G., KRINGELBACH M.L., PEARSON J. : Harmonic brain modes : a unifying framework for linking space and time in brain dynamics, *Neuroscientist*, 2018, 24, 277-293.
15. ATASOY S., VOHRYZEK J., DECO G., CARHART-HARRIS R.L., KRINGELBACH M.L. : Common neural signatures of psychedelics : Frequency-specific energy changes and repertoire expansion revealed using connectome-harmonic decomposition, *Progress in Brain Research*, 2018, 242, 97-120.  
Doi : 10.1016/hs.phr.2018.08.009
16. BAGGOTT M.J., COYLE J.R., EROWID E., EROWID F., ROBERTSON L.C. : Abnormal visual experiences in individuals with histories of hallucinogen use : A Web-based Questionnaire, *Drug and Alcohol Dependence*, 2011, 114(1), 61-67.
17. BAGGOTT M.J. : Psychedelics and creativity : A review of the quantitative literature (No. e1468). San Diego, CA, PeerJ PrePrints, 2015.
18. BARBEAU H., ROSSIGNOL S. : The effects of serotonergic drugs on the locomotor pattern and on cutaneous reflexes of the adult chronic spinal cat, *Brain Research*, 1990, 514, 55-67.  
Doi : 10.1016/00068993(90)90435-E
19. BARRIGAR R.H. : Regulation of psychedelic drugs, *Psychedelic Review*, 1964, 1, (4), 394-441.
20. BARKER S.A. : N,N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen : Past, Present, and Future Research to Determine its Role and Function, *Frontiers in Neuroscience*, 2018, 12, article 536, 1-17.  
Doi : 10.3389/fnins.2018.00536
21. BARRETT F.S., SCHLIENZ N.J., LEMBEK N., WAQAS M., VANDREY R. : « Hallucinations » Following Acute Cannabis Dosing : A Case Report and Comparison to Other Hallucinogenic Drugs, *Cannabis and Cannabinoid Research*, 2018, 3, 1, 85-93.  
Doi : 10.1089/can.2017.0052
22. BASAR E., GUNTEKIN B. : Darwin's evolution theory, brain oscillations, and complex brain function in a new 'Cartesian view' [Review], *International Journal of Psychophysiology*, 2009, 71, 1, 2-8.
23. BASCHARD P., RICHARD D. : Les stupéfiants. 2° partie : les drogues hallucinogènes, *Les Actualités Pharmaceutiques*, 1984, 213, 61-74.
24. BASTOS A.M., USREY W.M., ADAMS R.A. et al. : Canonical microcircuits for predictive coding, *Neuron*, 2012, 76, 695-711.

25. BAUMEISTER D., BARNES G., GIAROLI G., TRACY D. : Classical hallucinogens as antidepressants ? A review of pharmacodynamics and putative clinical roles, *Therapeutic Advances in Psychopharmacology*, 2014, 4, (4), 156-169.  
Doi : 10.1177/2045125314527985
26. BEÏQUE J.-C., IMAD M., MLADENOVIC L., GINGRICH J.A., ANDRADE R. : Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex, *PNAS*, 2017, 104, (23), 9870-9875.  
Doi : 10.1073/pnas.0700436104
27. BELOUIN S.J., HENNINGFIELD J.E. : Psychedelics : Where we are now, why we got here, what we must do, *Neuropharmacology*, 2018, 142, 7-19.  
Doi : 10.1016/j.neuropharm.2018.02.018
28. BENDER L., SIVA SANKAR D.V. : Chromosome Damage Not Found in Leukocytes of Children Treated with LSD-25, *Science*, 1968, 159, (3816), 749.
29. BENSOUSSAN P., JOANNIDÈS A.A. : A propos de l'expérience psychédélique, *Annales Médico-Psychologiques*, 1967, I, 25, (1), 112-115.
30. BOIRE R.G. : On cognitive liberty, *The Journal of Cognitive Liberties*, 2001, 2, 1, 7-22.
31. BOULOGOURIS V., GLENNON J.C., ROBBINS T.W. : Dissociable effects of selective 5-HT2A and 5-HT2C receptor antagonists on serial spatial reversal learning in rats, *Neuropsychopharmacology*, 2008, 33, 8, 2007-2019.
32. BOUSO J.C., PALHANO-FONTES F., RODRIGUEZ-FORNELLS A. et al. : Long-term use of psychedelic drugs is associated with difference in brain structure and personnalité in humans, *European Neuropsychopharmacology*, 2015, 25, (4), 483-492.  
Doi : 10.1016/j.euroneuro.2015.01.008
33. BOUTROS N., BOWERS M. : Chronic substance-induced psychotic disorders : State of the Literature, *Journal of Neuropsychiatry and Clinical Neurosciences*, 1996, 8, (3), 262-269.
34. BRAVO G., GROB C.S. : Psychedelics and transpersonnal psychiatry, in B.W. Scotton, A.B. Chinen & J.R. Battista (Eds.) *Textbook of transpersonnal psychiatry and psychology*, New York, Basic Book, 1996, pp 176-183.
35. BREAKY W. et al. : Hallucinogenic Drugs as Precipitants of Schizophrenia, *Psychological Medicine*, 1974, 4, (3), 255-261.
36. BRETEAU M., de la TOUR du PIN : Initiation à la pharmacologie des alcaloïdes de l'ergot de seigle, Laboratoires Sandoz SARL, Rueil Malmaison.
37. BRODIE B.B., SHORE P.A. : A concept for a role of serotonin and norepinephrine as chemical mediators in the brain, *Annals of the New York Academy of Sciences*, 1957, 66, (1), 631-642.
38. BROGAARD B., GATZIA D.E. : Psilocybin, Lysergic Acid Diethylamide, Mescaline, and Drug-Induced Synesthesia, Chapter 83, in « *Neuropathology of Drug Addictions and Substances Misuse, Volume 2, Chapter 83* », 2016, 890-905.  
Doi : 10.1016/B978-0-12-800212-4.00083-2
39. BROSSAIS P. : Les « designer drugs », *Psychotropes*, 1998, 4, 1, 83-101.
40. BROWN J.B., BROWN J.M. : The Psychedelic Gospel. The secret History of Hallucinogens in Christianity, Park Street Press, Rochester - Vermont, Toronto - Canada, 2016.
41. BROWN R.T., NICHOLAS C.R., COZZI N.V., GASSMAN M.C., COOPER K.M., MULLER D., ... HUTSON P.R. : Pharmacokinetics of escalating doses of oral psilocybin in healthy adults, *Clinical Pharmacokinetics*, 2017, 56, (12), 1543-1554.

42. BRUHN J.G., De SMET P.A., EL-SEEDI H.R. et al. : Mescaline use for 5700 years, *The Lancet*, 2002, 359, (9320), 1866.
43. CALVEY T., HOWELLS F.M. : An introduction to psychedelic neuroscience, *Progress in Brain Research*, 2018, 242, 1-23.  
Doi : 10.1016/bs.pbr.2018.09.013
44. CANAL C.E., MURNANE K.S. : The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens, *Journal of Psychopharmacology*, 2017, 31, (1), 127-143.
45. CARHART-HARRIS R. L., ERRITZOE D., WILLIAMS T. et al. : Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin, *Proceedings of the National Academy of Sciences*, 2012, 109, 2138-2143.
46. CARHART-HARRIS R. L., FRISTON K.J. : The default-mode, ego-functions and free-energy : A neurobiological account of Freudian ideas, *Brain*, 2010, 133, 4, 1265-1283.
47. CARHART-HARRIS R. L., LEECH R., HELLYER P.J., SHANAHAN M., FEILDING A., TAGLIAZUCCHI, E., CHIALVO D. R., NUTT D. : The entropic brain, A theory of conscious states informed by neuroimaging research with psychedelic drugs, *Frontiers in Human Neuroscience*, 2014, 8, (20), 1-22.  
Doi : 10.3389/fnhum.2014.00020
48. CARHART-HARRIS R. L., NUTT D. : Was it a vision or a waking dream? *Consciousness Research*, 2014, 5, 255.
49. CARHART-HARRIS R. L., KAELEN M., NUTT D. : How do hallucinogens work on the brain, *The Psychologist*, 2014, 27, 9, 662-665.  
<https://thepsychologist.bps.org.uk/volume-27/edition-9/how-do-hallucinogens-work-brain>
50. CARHART-HARRIS R. L., MUTHUKUMARASWAMY S., ROSEMAN L., KAELEN M., ... NUTT D. et al. : Neural correlates of the LSD experience revealed by multimodal neuroimaging, *PNAS (Proceedings of The National Academy of Sciences of the USA)*, 2016, 113, 17, 4853-4858.  
Doi : 10.1073/pnas.1518377113
51. CARHART-HARRIS R. L., KAELEN M., BOLSTRIDGE M., WILLIAMS T.M., WILLIAMS L.T., UNDERWOOD R., FEILDING A., NUTT D. : The paradoxical psychological effects of lysergic acid diethylamide (LSD), *Psychological Medicine*, 2016, 46, 1379-1390.
52. CARHART-HARRIS R., NUTT D. : Serotonin and brain function : a tale of two receptors, *Journal of Psychopharmacology*, 2017, 31, (9), 1091-1120.  
Doi : 10.1177/0269881117725915
53. CARHART-HARRIS R.L., GOODWIN G.M. : The Therapeutic Potential of Psychedelic Drugs : Past, Present, and Future, *Neuropsychopharmacology*, 2017, 42, 2105-2113  
Doi : 10.1038/npp.2017.84
54. CARHART-HARRIS R.L., ERRITZOE D., HAIJEN E., KAELEN M., WATTS R. : Psychedelics and connectedness, *Psychopharmacology*, 2017, 235, 547-550.  
Doi : 10.1007/s00213-017-4701-y
55. CARHART-HARRIS R.L., ROSEMAN L., HAIJEN E., ERRITZOE D., BRANCHI I., KAELEN M. : Psychedelics and the essential importance of context, *Journal of Psychopharmacology*, 2018, 32, 725-731.  
Doi : 10.1177/0269881118754710

56. CARHART-HARRIS R. L., FRISTON K.J. : REBUS and the Anarchic Brain : Toward a Unified Model of the Brain Action of Psychedelics, *Pharmacological Reviews*, 2019, 71, 316-344  
*doi : 10.1124/pr.118.017160*
57. CELADA P., PUIG V.M., DIAZ-MATAIX L., ARTIGAS F. : The hallucinogen DOI reduces low-frequency oscillations in rat prefrontal cortex, *Biological Psychiatry*, 2008, 64, 5, 392-400.
58. CIPRIAN-OLLIVIER J., CETKOVICH-BAKMAS M.G. : Altered consciousness states and endogenous psychoses : a common molecular pathway ? *Schizophrenia Research*, 1997, 28, 257-265.
59. CLARK W.H., FUNKHOUSER G.R. : Physicians and researchers disagree on psychedelic drugs, *Psychology Today*, 1970, 3 (11), 48-50, 70-73.
60. COHEN S. : Psychotomimetic agents, *Annual Review of Pharmacology*, 1967, 7, (1), 301-318.
61. COLE J.O., KATZ M.M. : The Psychotomimetic Drugs : An Overview, *JAMA*, 1964, 187, 758-761.  
<http://druglibrary.net/schaffer/lsd/colekatz.htm>
62. COPLAND J.-D., GORMAN J.-M. : Detectable levels of fluoxetine metabolites after discontinuation : an unexpected serotonin syndrome, *American Journal of Psychiatry*, 1993, 150, 837.
63. CUNNINGHAM N. : Hallucinogenic plants of abuse, *Emergency Medicine Australasia*, 2008, 20, (2), 167-174.
64. De ARAUJO D.B., RIBEIRO S., CECCHI G.A. et al. : Seeing with the eyes shut: Neural basis of enhanced imagery following ayahuasca ingestion, *Human Brain Mapping*, 2012, 33, 11, 2550-2560.
65. DELAY J. : Classification of psychotropic drugs, in « *Psychopharmacology Frontiers* », N.S. Kline Ed., London, Churchill, 1959, 426-428.
66. DOBLIN R. : Regulation of the medical use of psychedelics and marijuana, Harvard University dissertation, 2001.  
<http://www.maps.org/news/332-maps-resources/research-papers/5402-dissertation-rick-doblin-ph-d>
67. DOBLIN R.E., CHRISTIANSEN M., JEROME L., BURGE B. : The Past and Future of Psychedelic Science : An Introduction to this Issue, *Journal of Psychoactive Drugs*, 2019, 51, (2), 93-97.  
Doi : 10.1080/02791072.2019.1606472
68. Dos SANTOS R.G., OSORIO F.L., CRIPPA J.A.S., HALLAK J.E.C. : Classical hallucinogens and neuroimaging : A systematic review of human studies : Hallucinogens and neuroimaging, *Neuroscience & Biobehavioral Reviews*, 2016, 71, 715-728.  
Doi : 10.1016/j.neubiorev.2016.10.026
69. EDEL Y. : Expérimentations des psychodysleptiques à Sainte-Anne dans les années 1960, *Annales Médico-Psychologiques*, 2017, 175, 653-660.  
Doi : 10.1016/j.amp.2017.08.003
70. ELSEY J. W. : Psychedelic drug use in healthy individuals: a review of benefits, costs, and implications for drug policy, *Drug Science, Policy and Law*, 2017, 3, 1-11.  
Doi : 10.1177/2050324517723232
71. FANTEGROSSI W.E., HARRINGTON A.W., ECKLER J.R., ARSHAD S., RABIN R.A., WINTER J.C., COOP A., RICE K.C., WOODS J.H. : Hallucinogen-like actions of 2,5-

- dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats, *Psychopharmacology (Berl)*, 2005, 181, (3), 496-503.  
 Doi : 10.1007/s00213-005-0009-4
72. FANTEGROSSI W.E., MURNANA K.S., REISSIG C.J. : The behavioral pharmacology of hallucinogens, *Biochemical Pharmacology*, 2008, 75, 17-33.  
 Doi : 10.1016/j.bcp.2007.07.018
73. FANTEGROSSI W.E., REISSIG C.J., KATZ E.B., YAROSH H.L., RICE K.C., WINTER J.C. : Hallucinogen-like effects of N,N-dipropyltryptamine (DPT) : possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents, *Pharmacology Biochemistry and Behavior*, 2008, 88, (3), 358-365.  
 Doi : 10.1016/j.pbb.2007.09.007
74. FORSTMANN M., SAGIOGLOU C. : Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness, *Journal of Psychopharmacology*, 2017 31, 975-988.  
 Doi : 10.1177/0269881117714049
75. FORTIER M. : Le sens de réalité dans les expériences psychotropes, Étude comparée des hallucinogènes sérotoninergiques et anticholinergiques, in Baud S., « *Histoires et usages de plantes psychotropes* », Imago, Paris, 2017, 125-184.
76. FREEDMAN D. X. : On the use and abuse of LSD, *Archives of General Psychiatry*, 1968, 18, (3), 330-347.  
 Doi : [10.1001/archpsyc.1968.01740030074008](https://doi.org/10.1001/archpsyc.1968.01740030074008)
77. FREEDMAN DX : Problems and prospects of research with the hallucinogens, in : Gamage JR, Zerkin EL (eds) "Hallucinogenic drug research : impact on science and society", Stash Press, Beloit, 1970.
78. FROKJAER V.G., MORTENSENE. L., NIELSEN. Å., HAUGBOL S., PINBORG L. H., ADAMS K. H. et al. : Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder. *Biological Psychiatry* , 2008, 63, 6, 569-576.
79. FROKJAER V.G., MORTENSENE. L., NIELSEN. Å., HAUGBOL S., PINBORG L. H., ADAMS K. H. et al. : Frontolimbic serotonin 2A receptor binding in healthy, *Frontiers in Pharmacology*, 2018, 9, Article 897.
80. GANDEVIA S.C. : Self-experimentation, ethics, and efficacy, *Monash Bioethic Review*, 2005, 23, (4).
81. GLASS G, BOWERS M. : Chronic Psychosis Associated with Long-term Psychotomimetic Drug Use, *Archives of General Psychiatry*, 1970, 23, (2), 97-103.
82. GLENNON R.A., ROSECRANS J.A., YOUNG R., Drug-induced discrimination : a description of the paradigm and a review of its specific application to the study of hallucinogenic agents, *Medicinal Research Reviews*, 1983, 3, 289-340.
83. GLENNON R.A., YOUNG R., JACYNO J.-M., SLUSHER M., ROSECRANS J.A. : DOM-stimulus generalization to LSD and other indolealkylamines, *European Journal of Pharmacology*, 1983, 86, 453-459.
84. GLENNON R.A., TITELER M., McKENNEY J.D. : Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents, *Life Sciences*, 1984, 35, (25), 2505-2511.
85. GLENNON R.A. : Classical Hallucinogens : An Introductory Overview, in « Hallucinogens : An Update », Editors : Geraldine C. Lin, Ph.D., National Institute on Drug Abuse, Richard A. Glennon, Ph.D., Virginia Commonwealth University, NIDA Research Monograph 146, 1994, 52-73.
- <https://archives.drugabuse.gov/sites/default/files/monograph146.pdf>

86. GOBBI M., MOIA M., PIRONA L., CEGLIA I., REYES-PARADA M., SCORZA C., MENNINI T. : p-Methylthioamphetamine and 1-(m-chlorophenyl)piperazine, two non-neurotoxic 5-HT releasers in vivo, differ from neurotoxic amphetamine derivatives in their mode of actions at 5-HT nerve endings in vitro, *Journal of Neurochemistry*, 2002, 82, (6), 1435-1443.
87. GODA S.A., PIASECKA J., OLSZEWSKI M., KASICKI S., HUNT M.J. : Serotonergic hallucinogens differentially modify gamma and high frequency oscillations in the rat nucleus accumbens, *Psychopharmacology (Berl)*, 2013, 228, (2), 271-282.  
Doi : 10.1007/s00213-013-3057-1
88. GODDARD J.L. : Organization and coordination of Federal Drug Research and regulatory programs : LSD : hearings before the United States Senate Committee on Government Operations, Subcommittee on Executive Reorganization, Eighty-Ninth Congress, Second Session, 1966.
89. GOUZOULIS-MAYFRANK E., HEEKEREN K., THELEN B., LINDENBLATT H., KOVAR K.A., SASS H., GEYER M.A. : Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans, *Behavioural Pharmacology*, 1998, 9, (7), 561-566.
90. GOUZOULIS-MAYFRANK E., HERMLE L., THELEN B., SASS H. : History, rationale and potential of human experimental hallucinogenic drug research in psychiatry, *Pharmacopsychiatry*, 1998, 31, (S 2), 63-68.
91. GOUZOULIS-MAYFRANK E., SCHRECKENBERGER M., SABRI O., ARNING C., THELEN B., SPITZER M., ... SASS H. : Neurometabolic effects of psilocybin, 3, 4-methylenedioxymethamphetamine (MDMA) and d-methamphetamine in healthy volunteers: A double-blind, placebo-controlled PET study with [18F] FDG, *Neuropsychopharmacology*, 1999, 20, (6), 565-581.
92. GOUZOULIS-MAYFRANK E., THELEN B., HABERMEYER E., KUNERT H. J., KOVAR K. A., LINDENBLATT H., ... SASS H. : Psychopathological, neuroendocrine and autonomic effects of 3, 4-methylenedioxymethamphetamine (MDMA), psilocybin and d-methamphetamine in healthy volunteers Results of an experimental double-blind placebo- controlled study, *Psychopharmacology*, 1999, 142, (1), 41-50.
93. GRELLA B., DUKAT M., YOUNG R., TEITLER M., HERRICK-DAVIS K., GAUTHIER C.B., GLENNON R.A. : Investigation of hallucinogenic and related β-carbolines, *Drug and Alcohol Dependence*, 1998, 50, 99-107.
94. GRIFFITHS R.R., RICHARDS W.A., McCANN U., JESSE R. : Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance, *Psychopharmacology (Berl)*, 2006, 187, 3, 268-283; discussion 284-292.
95. GRIFFITHS R. R., GROB C. S. : Hallucinogens as medicine, *Scientific American*, 2010, 303, 76-79.  
doi: 10.1038/scientificamerican1210-76
96. GRIFFITHS R. R., JOHNSON M. W., CARDUCCIM. A., UMBRICHT A., RICHARDS W. A., RICHARDS B. D. et al. : Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial, *Journal of Psychopharmacology*, 2016, 30, 1181-1197.  
Doi : 10.1177/0269881116675513

97. GRIFFITHS R. R., JOHNSON M. W., Richards, W. A., Richards, B. D., McCANN U., JESSE R. : Psilocybin occasioned mystical-type experiences : immediate and persisting dose-related effects, *Psychopharmacology*, 2011, 218, 649–665.  
Doi : 10.1007/s00213-011-2358-5
98. GRIFFITHS R. R., RICHARDS W. A., JOHNSON M. W., McCANN U., D., JESSE R. : Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later, *Journal Psychopharmacology*, 2008, 22, 621–632. doi: 10.1177/0269881108094300
99. GRIFFITHS R. R., RICHARDS W. A., McCANN U.D., JESSE R. : Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance, *Psychopharmacology*, 2006, 187, 268–283.  
Doi : 10.1007/s00213-006-0457-5
100. GRINSPOON L., BAKALAR J.B. : Psychedelic Drugs Reconsidered, New York, Basic Books, 1979.
101. GROB C. S. : Psychiatric research with hallucinogens : what have we learned ?, *The Heffter Review of Psychedelic Research*, 1998, 1, 8-20.
102. HAIJEN E. et al. : Predicting Responses to Psychedelic Drugs subjects is associated with personality risk factors for affective disorder, *Biological Psychiatry*, 2007, 63, 569–576.  
Doi : 10.1016/j.biopsych.2007.07.009
103. HAÏJEN E.C.H.M., KAELEN M., ROSEMAN L., TIMMERMANN C., KETTNER H., RUS S., NUTT D., DAWS R.E., HAMPSHIRE A.D.G., LORENZ R., CARHART-HARRIS R.L. : Predicting Responses to Psychedelics : A Prospective Study, *Frontiers in Pharmacology*, 2018, 9, article 897.  
Doi : 10.3389/fphar.2018.00897
104. HALBERSTADT A.L., GEYER M.A. : Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens, *Neuropharmacology*, 2011, 61, (3), 364-381.  
Doi : 10.1016/j.neuropharm.2011.01.017
105. HALBERSTADT A.L. : Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. *Behavioural Brain Research*, 2015, 277, 99–120.  
Doi : 10.1016/j.bbr.2014.07.016
106. HALPERN J., POPE H. : Hallucinogen persisting perception disorder : what do we know after 50 years ?, *Drug and Alcohol Dependence*, 2003, 69, (2), 109–119.
107. HARMAN W.W., McKIM R.H., MOGAR R.E. et al. : Psychedelic agents in creative problem-solving, *Psychological Reports*, 1996, 19, 211–227.
108. HARTOGSOHN I. : Set and setting, psychedelics and the placebo response : An extra-pharmacological perspective on psychopharmacology, *Journal of Psychopharmacology*, 2016, 30, (12), 1259–1267.  
Doi : 10.1177/0269881116677852
109. HARTOGSOHN I. : Constructing drug effects: a history of set and setting, *Drug Science, Policy and Law*, 2017, 3, 1-17.  
Doi : 10.1177/2050324516683325
110. HARVEY J.A. : Role of the serotonin 5-HT (2A) receptor in learning, *Learning and Memory*, 2003, 10, 5, 355–362.
111. HARVEY J.A., QUINN J.L., LIU R. et al. : Selective remodeling of rabbit frontal cortex, *Psychopharmacology (Berl)*, 2004, 172(4), 435–442.

112. HAUTEFEUILLE M. VELEA D. : Les Drogues de Synthèse, Paris, Presses Universitaires de France, coll. « *Que Sais-Je ?* », 2002.
113. HENDRICKS P.S., THORNE C.B., CLARK C.B., COOMBS D.W., JOHNSON M.W. : Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population, *Journal of Psychopharmacology*, 2015, 29, (3), 280–288.  
Doi : 10.1177/0269881114565653
114. HENDRICKS P. S., CRAWFORD M. S., CROPSEY K. L., COPES H., SWEAT N. W., WALSH Z. et al. : The relationships of classic psychedelic use with criminal behavior in the United States adult population, *Journal of Psychopharmacology*, 2017, 32, 37–48.  
Doi : 10.1177/0269881117735685
115. HERMLE L., SIMON M., RUCHSOW M., GEPPERT M. : Hallucinogen-persisting perception disorder, *Therapeutic Advances in Psychopharmacology*, *SAGE Journals*, 2012, 2, 5, 199-205.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736944/>
116. HOFFER A., OSMOND H. : The hallucinogens, New York, Academic Press, 1967.
117. HOFMANN A. : LSD : My Problem Child, 1976.
118. HOFFMAN A.J., NICHOLS D.E. : Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives, *Journal of Medical Chemistry*, 1985, 28, (9), 1252-1255.
119. HOLLISTER L.E., *Chemical Psychoses : LSD and Related Drugs*, Springfield, USA, Charles C. Thomas, 1968.
120. HOLZE F., VIZELI P., MÜLLER LEY L., DUERIG R., VARGHESE N., ECKERT A., BORGWARDT S., LIECHTI M.E. : Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects (ClinicalTrials.gov NCT03019822), Author Manuscript, 2019.  
Doi : 10.1038/s41386-019-0569-3
121. HOOD Jr R. W. : The construction and preliminary validation of a measure of reported mystical experience, *Journal for the Scientific Study of Religion*, 1975, 14, 29–41.  
Doi : 10.2307/1384454
122. INABA D. S., COHEN W. E. : Excitants, calmants, hallucinogènes, Padova, Italie, Piccin Nuova Libraria, version française, 1997.
123. ISBELL H., WOLBACH A.B., WIKLER A., MINER E.J. : Cross tolerance between LSD and psilocybin, *Psychopharmacologia*, 1961, 2, 147-59.
124. JACOB III P., SHULGIN A.T. : Structure-Activity Relationships of Classic Hallucinogens and their Analogs, in « Hallucinogens : An Update », Editors : Geraldine C. Lin, Ph.D., National Institute on Drug Abuse, Richard A. Glennon, Ph.D., Virginia Commonwealth University, NIDA Research Monograph 146, 74-91.  
<https://archives.drugabuse.gov/sites/default/files/monograph146.pdf>
125. JAHAL B. : The neuropharmacology of sleep paralysis hallucinations : serotonin 2A activation and a novel therapeutic drug, *Psychopharmacology*, 2018, 235, 3083-3091. doi.org/10.1007/s00213-018-5042-1  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208952/>
126. JANIGER O. : The use of hallucinogenic agents in psychiatry, *Californian Clinician*, 1959, 55, 222-224, 251-259.

127. JANOS B.K., PETER K. : Research ethics aspects of experimentation with LSD on human subjects : a historical and ethical review, *Medicine, Health Care and Philosophy*, 2018, 11 p.  
Doi : 10.1007/s11019-018-9871-9
128. JEROME L., MOJEIKO V., DOBLIN R. : Afterword : the psychedelic research renaissance – A review of recent Psychedelic Psychotherapy Research, in "LSD Psychotherapy", MAPS, CA, USA, 361 – 373.
129. JOHANSEN P.O., KREBS T.S. : Psychedelics not linked to mental health problems or suicidal behavior : A population study, *Journal of Psychopharmacology*, 2015, 29, (3), 270–279.  
Doi: 10.1177/0269881114568039
130. JOHNSON M.W., RICHARDS W.A., GRIFFITHS R.R. : Human Hallucinogen Research : Guidelines for Safety, *Journal of Psychopharmacology*, 2008, 22, (6), 603-620.  
Doi : 10.1177/0269881108093587
131. JOHNSON M.W., GARCIA-ROMEU A., JOHNSON P.S., GRIFFITHS R.R. : An online survey of tobacco smoking cessation associated with naturalistic psychedelic use, *Journal of Psychopharmacology*, 2017, 31, 841–850.  
Doi : 10.1177/0269881116684335
132. JOHNSON M.W., HENDRICKS P.S. , BARRETT F.S., GRIFFITHS R.R. : Classic psychedelics : An integrative review of epidemiology, therapeutics, mystical experience, and brain network function, *Pharmacology & Therapeutics*, 2019. <https://doi.org/10.1016/j.pharmthera.2018.11.010>
133. JOYCE I. : A comparative literature survey of psilocybin and LSD-25 metabolism, *Capstone Project*, Cal Poly Pomona, Winter 2017. [http://broncoscholar.library.cpp.edu/bitstream/handle/10211.3/193166/Joyce\\_Ian\\_LibrarResearchPaper2017.pdf](http://broncoscholar.library.cpp.edu/bitstream/handle/10211.3/193166/Joyce_Ian_LibrarResearchPaper2017.pdf)
134. JUNGABERLE H., THAL S., ZEUCH A., ROUGEMENT-BÜCKING A., von HEYDEN M., AICHER H., SCHEIDEGGER M. : Positive psychology in the investigation of psychedelics and entactogens : A critical review, *Neuropharmacology*, 2018.  
Doi : 10.1016/j.neuropharm.2018.06.034
135. KAELEN M., BARRET F., ROSEMAN L., LORENZ R., FAMILY N., BOLSTRIDGE, M. et al. : LSD enhances the emotional response to music, *Psychopharmacology*, 2015, 232, 3607–3614.  
Doi : 10.1007/s00213-015-4014-y
136. KAELEN M., ROSEMAN L., KAHAN J., SANTOS-RIBEIRO A., ORBAN C., LORENZ R. et al. : LSD modulates music-induced imagery via changes in para-hippocampal connectivity, *European Neuropsychopharmacology*, 2016, 26, 1099–1109.  
Doi : 10.1016/j.euroneuro.2016.03.018
137. KAELEN M., GIRIBALDI B., RAINES J., EVANS L., TIMMERMANN-SLATER, C., RODRIGUEZ N., ... CARHART-HARRIS R., et al. : The hidden therapist : evidence for a central role of music in psychedelic therapy, *Psychopharmacology*, 2017, 235, (2), 505–519.  
Doi : 10.1007/s00213-017-4820-5
138. KAELEN M., LORENZ R., BARRETT F.S., ROSEMAN L., ORBAN C., SANTOS-RIBEIRO A. et al. : Effects of LSD on music-evoked brain activity, *bioRxiv.org*, 2017, 153031.

Doi : 10.1101/153031

139. KELLY J.R., BAKER A., BABIKER M., BURKE L., BRENNAN C., O'KEANE V. : The psychedelic renaissance : the next trip for psychiatry ?, *Irish Journal of Psychological Medicine*, 2019, 1-5.  
Doi : 10.1017/ipm.2019.39
140. KIEFFER S.N. : Psychedelic drugs, *Pa Med*, 1968, 71, (4), 57-67.
141. KIMURA T., OHTA T., WATANABE K., YOSHIMURA H., YAMAMOTO I. : Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5HT) receptor, *Biological and Pharmaceutical Bulletin*, 1998, 21, 224-226.
142. KLAVETTER R.E., MOGAR R.E. : Peak experiences: investigation of their relationship to psychedelic therapy and self-actualization, *Journal of Humanistic Psychology*, 1967, 7, 171-177.  
Doi : 10.1177/002216786700700206
143. KOMETER M., VOLLENWEIDER F.X. : Serotonergic Hallucinogen-Induced Visual Perceptual Alterations, *Current Topics in Behavioral Neurosciences*, 2016,  
Doi : 10.1007/7854\_2016\_461
144. KRAEHENMANN R., POKORNY D., VOLLENWEIDER L., PRELLER K.H., POKORNY T., SEIFRITZ E., VOLLENWEIDER F.X. : Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation, *Psychopharmacology*, 2017, 234, (13), 2031-2046.
145. KRAEHENMANN R., PRELLER K.H., SCHEIDEGGER M., POKORNY T., BOSCH O.G., SEIFRITZ E., VOLLENWEIDER F.X. : Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers, *Biological Psychiatry*, 2015, 78, (8), 572-581.
146. KRAEHENMANN R., SCHMIDT A., FRISTON K., PRELLER K. H., SEIFRITZ E., VOLLENWEIDER F. X. : The mixed serotonin receptor agonist psilocybin reduces threatinduced modulation of amygdala connectivity, *NeuroImage : Clinical*, 2016, 11, 53-60.
147. KREBS T.S., JOHANSEN P.-Ø. : Psychedelics and mental health : a population study. *PloS One*, 2013, 8, 8, e63972.
148. KREBS T.S., JOHANSEN P.-Ø. : Over 30 million psychedelic users in the United States. *F1000Research*, 2013, 2, 98.  
Doi : 10.12688/f1000research.2-98.v1
149. LANGLITZ N. : Neuropsychedelia : The revival of Hallucinogen Research Since the decade of the Brain, University of California Press, Berkeley and Los Angeles, California, 2013.
150. LANGLITZ N. : Psychedelics can't be tested using conventional clinical trial, *Aeon Ideas*, 2015.  
<https://aeon.co/ideas/psychedelics-can-t-be-tested-using-conventional-clinical-trial>
151. LETHEBY C. : The Philosophy of Psychedelic transformation, *Journal of Consciousness Studies*, 2015, 22 (9-10), 170-193.
152. LETHEBY C. : The epistemic innocence of psychedelic states, *Consciousness and Cognition*, 2016, 39, 28-37.
153. LETHEBY C. : Naturalizing Psychedelic Spirituality, *Zygon*, 2017, 174, 52, 3, 30 p.  
Doi : 10.1111/zgyo.12353

154. LETHEBY C. : The Varieties of Psychedelic Epistemology, in N. Wyrd, D. Luke, A. Tollar, C. Adams and D. King (eds.) : « *Psychedelicacies : more food for thought from Breaking Convention* », Strange Attractor Press, 2019.15 p.
155. LEWIN L. : Phantastica : A classic survey on the use and abuse of mind-altering plants, Rochester, VT, Park Street Press, 1931/1998.
156. LIFSHITZ M., SHEINER E., KIRMAYER L. : Cultural Neurophenomenology of Psychedelic Thought : Guiding the “Unconstrained” Mind Through Ritual Context, The Oxford Handbook of Spontaneous Thought : Mind-Wandering, Creativity, and Dreaming, Edited by Kalina Christoff and Kieran C.R. Fox, *Oxford Handbooks Online*, 2018.  
Doi : 10.1093/oxfordhb/9780190464745.013.4
157. LOPEZ-GIMENEZ J.F., GONZALEZ-MAESO J. : Hallucinogens and Serotonin 5-HT5A Receptor-Mediated Signaling Pathways, *Current Topics in Behavioral Neurosciences*, 2018, 36, 45-73.  
Doi : 10.1007/7854\_2017\_478
158. LUETHI D., HOENER M.C., LIECHTI M.E. : Effects of the new psychoactive substances diclofensins, diphenidine and methoxphenidine on monoaminergic systems, *European Journal of Pharmacology*, 2017, 24 p.  
Doi : 10.1016/j.ejphar.2017.12.012
159. LY C., GREB A.C., CAMERON L.P., OLSON D.E. et al : Psychedelics Promote Structural and Functionnal Neural Plasticity, *CellPress, Cell Reports* 23, 2018, 23, 3170-3182.  
Doi : 10.1016/j.celrep.2018.05.022
160. McBRIDE M.C. : Bufotenine: Toward an Understanding of Possible Psychoactive Mechanisms, *Journal of Psychoactive Drugs*, 2000, 32, 3, 321-331.  
<http://citeserx.ist.psu.edu/viewdoc/download?doi=10.1.1.690.8931&rep=rep1&type=pdf>
161. MEGEVAND P., GROPPE D.M., GOLDFINGER M.S. et al. : Seeing scenes : Topographic visual hallucinations evoked by direct electrical stimulation of the parahippocampal place area, *Journal of Neuroscience*, 2014, 34, 16, 5399–5405.  
<https://www.jneurosci.org/content/34/16/5399.long>
162. MISSA J.-N. : Naissance de la psychiatrie biologique, sciences, histoire et société, Paris, PUF, 2006, 378 p.
163. MONROE R.R. & HEATH R.G. : Effects of lysergic acid and various derivative on depth and cortical electrograms, *Journal of Neuropsychiatry*, 1961, 3, 75-82.
164. MÜLLER F., LIECHTI M.E., LANG U.E., BORGWARDT S. : Advances and challenges in neuroimaging studies on the effects of serotonergic hallucinogens : Contributions of the resting brain, *Progress in Brain Research*, 2018, 1-19.  
Doi : 10.1016/bs.phr.2018.08.004
165. MURNANE K.S. : The renaissance in psychedelic research : What do preclinical models have to offer, *Progress in Brain Research*, 2018, 242, 25-67.  
Doi : 10.1016/bs.pbr.2018.08.003
166. MUTHUKUMARASWAMY S.D., CARHART-HARRIS R.L., MORAN R.J. et al. : Broadband cortical desynchronization underlies the human psychedelic state. *Journal of Neuroscience*, 2013, 33, 38, 15171–15183.  
Doi : 10.1523/JNEUROSCI.2063-13.2013

167. MUZIO J.N., ROFFWARG H.P., KAUFMAN E. : Alterations in the nocturnal sleep cycle resulting from LSD, *Electroencephalography and Clinical Neurophysiology*, 1966, 21, 4, 313-324.
168. NICHOLS D. E. : Differences between the mechanism of action of MDMA, MBDB and the classic hallucinogens. Identification of a new therapeutic class : entactogens, *Journal of Psychoactive Drugs*, 1986, 18, 4, 305-313.
169. NICHOLS D.E. : Hallucinogens, *Pharmacology & Therapeutics*, 2004, 101, (2), 131-181.  
Doi : 10.1016/j.pharmthera.2003.11.002
170. NICHOLS D.E. : Psychedelics, *Pharmacological Reviews*, 2016, 68, 264-355.  
Doi : 10.1124/pr.115.011478
171. OLIEVENSTEIN C. : Contribution à l'étude du LSD-25 en clinique psychiatrique, Thèse pour le Doctorat de médecine, Paris, 1967.
172. ORSOLINI L., PAPANTI G.D., De BERARDIS D., GUIRGUIS A., CORKERY J.M., SCHIFANO F. : The « Endless Trip » among the NPS Users : Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review, *Frontiers in Psychiatry*, Volume 8, Article 240, 1-10.  
Doi : 10.3389/fpsyg.2017.00240
173. OSMOND H. : The medical and scientific importance of hallucinogens, *Practitioner*, 1973, 210, (255), 112-119.
174. PALLAVACINI C., VILAS M.G., VILLARREAL M., ZAMBERLAN F., MUTHUKUMARASWAMY S., NUTT D., CARHART-HARRIS R., TAGLIAZUCCHI E. : Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives, *NeuroImage*, 2019.  
Doi : 10.1016/j.neuroimage.2019.06.053
175. PAPASEIT E., PEREZ-MANA C., MATEUS J.-A., PUJADAS M., FONSECA F., TORRENS M., OLESTI E., de la TORRE R., FARRE M. : Human Pharmacology of Mephedrone in Comparison with MDMA, *Neuropsychopharmacology*, 2017.  
Doi : 10.1038/npp.2016.75
176. PASSIE Torsten : The Science of Microdosing Psychedelics, Psychedelic Press, London, UK, 2019.
177. PELLERIN C. : Trips. How hallucinogens work in your brain, Seven Stories Press, New York, 1998.  
<http://www.sevenstories.com/>
178. POIRIER M.F. : Les hallucinogènes, *Séminaire de Psychiatrie Biologique*, Ed. Fournier Frères -Pharmuka, 1992, 21, 61-72.
179. PRELLER K.H., HERDENER M., POKORNY T., PLANZER A., KRAEHENMANN R., STÄMPFLI P. et al. : The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation, *Current Biology*, 2017, 27, 451-457.  
Doi : 10.1016/j.cub.2016.12.030
180. PRELLER K.H., VOLLENWEIDER F.X. : Phenomenology, Structure, and Dynamic of Psychedelic States, *Current Topics in Behavioral Neurosciences*, 2018, 36, 221-256.  
Doi : 10.1007/7854\_2016\_459
181. PRELLER K.H., VOLLENWEIDER F.X. : Modulation of Social Cognition via Hallucinogens and « Entactogens », *Frontiers in Psychiatry*, 2019, 10, Article 881.  
Doi : 10.3389/fpsyg.2019.00881

182. PUSPANATHAN P. : Psychedelic Research in Australia : Breaking through the stigma, *Australian and New Zealand Journal of Psychiatry*, 2017, 51, 940-941.
183. RAICHLE M.E., MacLEOD A.M., SNYDER A.Z. et al. : A default mode of brain function, *Proceedings of the National Academy of Sciences*, 2001, 98, 676-682.
184. RAY T.S. : Psychedelics and the human receptorome, *PLOS One*, 2010, 5, (2), e9019.  
Doi : 10.1371/journal.pone.009019
185. RECH R.H., COMMISSARIS R.L. : Neurotransmitter basis of the behavioral effects of hallucinogens, *Neuroscience & Biobehavioral Reviews*, 1982, 6, (4), 521-527.  
PMID: 6817241
186. RICHARDS W.A. : Sacred Knowledge : Psychedelics and Religious Experiences, New York, NY, Columbia University Press, 2015.
187. RIBA J., ANDERER P., MORTE A. et al. : Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers, *British Journal of Clinical Pharmacology*, 2002, 53, 6, 613-628.
188. RICHARD D., SENON J. L. : Dictionnaire des drogues, des toxicomanies et des dépendances, Paris, Larousse, 1999, chapitre "hallucination", pp. 214-218.
189. RIGA M.S., SORIA G., TUDELA R. et al. : The natural hallucinogen 5-MeO-DMT, component of ayahuasca, disrupts cortical function in rats, *International Journal of Neuropsychopharmacology*, 2014, 17, 1269-1282.
190. ROMANO A.G., QUINN J.L., LI L. et al. : Intrahippocampal LSD accelerates learning and desensitizes the 5-HT (2A) receptor in the rabbit, *Psychopharmacology (Berl)*, 2010, 212, 3, 441-448.
191. ROMANO A.G., QUINN J.L., LIU R. et al. : Effect of serotonin depletion on 5-HT2A-mediated learning in the rabbit: evidence for constitutive activity of the 5-HT2A receptor in vivo, *Psychopharmacology (Berl)*, 2006, 184, 2, 173-181.
192. RUCK C., BIGWOOD J., STAPLES D., OTT J., WASSON G. : Entheogens, *The Journal of Psychedelic Drugs*, 1979, 11, (1-2), 145-146.
193. RUCK C., STAPLES B., HEINRICH C. : The apples of Apollo : Pagan and Christian mysteries of the eucharist, Durham, NC, Carolina Academic Press, 2001.
194. RUCKER J.J.H., ILIFF J., NUTT D.J. : Psychiatry & the psychedelic drugs. Past, present & future, *Neuropharmacology*, 2018, 142, 200-218.  
Doi : 10.1016/j.neuropharm.2017.12.040
195. RUDGLEY R. : Essential substances : A cultural history of intoxicants in society, New York, NY, Kodansha America, 1994.
196. SALIH L.H., KAUSHIK A. : Mini Review on Psychedelic Drugs : Illumination on the Hidden Aspects of Mind, *American Journal of Phytomedicine and Clinical Therapeutics*, 2013, 1, 5, 432-444.
197. SAYIN Ü. : A Comparative Review of the Neuro-Psychopharmacology of Hallucinogen-Induced Altered States of Consciousness : The Uniqueness of Some Hallucinogens, *NeuroQuantology*, 2012, 10, (2), 316-340.
198. SCHULTES R.E., HOFMANN A. : The Botany and Chemistry of Hallucinogens, Charles C. Thomas, Springfield, IL, 1973.
199. SCHULTES R.E. : Antiquity of the Use of New World hallucinogens, *The Heffter Review of Psychedelic Research*, 1998, 1 1-7.
200. SCHWARZ B.E., SEM-JACOBSEN C.W., PETERSEN M.C. : Effects of mescaline, LSD-25, and adrenochrome on depth electrograms in man, *AMA Archives of Neurology and Psychiatry*, 1956, 75, 6, 579-587.

201. SCOTT G., CARHART-HARRIS R.L. : Psychedelics as a treatment for disorders of consciousness, *Neuroscience of Consciousness*, 2019, 5, (1), niz003  
doi: 10.1093/nc/niz003
202. SENON J. L. : Les psychostimulants : définition, classification et activité, *Séminaire de Psychiatrie Biologique*, Editions Fournier Frères - Pharmuka, 1985, Tome VIII, 61-73.
203. SESSA B. : Can psychedelics have a role in psychiatry once again ?, *British Journal of Psychiatry*, 2005, 186, 457-458  
Doi : 10.1192/bjp.186.6.457
204. SESSA B. : Shaping the renaissance of psychedelic research, *Lancet*, 2012, 380, (9838), 200-201.  
Doi : 10.1016/S0140-6736(12)60600-X
205. SESSA B. : Why Psychiatry needs psychedelics and psychedelics need psychiatry, *Journal of Psychoactive Drugs*, 2014, 46, (1), 57-62.  
Doi : 10.1080/02791072.2014.877322
206. SESSA B : To Fathom Hell or Soar Angelic, Psychedelic Press, Falmouth, Cornwall, 2015.
207. SESSA B. : Can 3,4-methylenedioxymethamphetamine therapy, be used to treat alcohol use disorder ?, *Journal of Psychedelic Studies*, 2017, 1, (1), 1-9.  
Doi : 10.1556/2054.01.2016.003
208. SESSA B. : Why Psychiatry Needs 3,4-methylenedioxymethamphetamine : A Child Psychiatrist 's Perspective, *Neurotherapeutics*, 2017, 14, (3), 741-749.  
Doi : 10.1007/s13311-017-0531-1
209. SESSA B. : The Psychedelic Renaissance, Reassessing the Role of Psychedelic Drugs, in « *21st Century Psychiatry and Society* », London, UK, Muswell Hill Press, 2017.
210. SESSA B., HIGBED L., NUTT D. : A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy, *Frontiers in Psychiatry*, 2019, 7 p.  
Doi : 10.3389/fpsyg.2019.00138
211. SHULGIN Al., SHULGIN An. : PIKHAL : a chemical love story, Berkeley, Transform Press, 1991/1995.
212. SHULGIN A. T. : TIHKAL. The continuation, Berkeley, California, USA, Transform Press, 1993.
213. SIMMLER L.D., LIECHTI M.E. : Pharmacology of MDMA- and Amphetamine-Like New Psychoactive Substances, Springer Nature, *Handbook of Experimental Pharmacology*, 2018.  
Doi : 10.1007/164\_2018\_113
214. SMITH H. : Cleansing the doors of perception : The religious significance of entheogenic plants and chemicals, New York, NY, Penguin Putnam, 2000.
215. SPIRIT PHARMACIST : On Psychotropics & Psychedelics : To Taper or Not to Taper, February 28, 2020, 1-9.  
<https://www.spiritpharmacist.com/blog/2020/2/28/on-psychotropics-and-psychedelics-to-taper-or-not-to-taper>
216. SPIRIT PHARMACIST : Antipsychotic & Psychedelics : Historical Perspectives & Contemporary Application, 2019, 1-8.  
[https://www.spiritpharmacist.com/blog/2019/12/7/r77mfas7zqfpqdf3azr6xtx\\_n4qa4c9](https://www.spiritpharmacist.com/blog/2019/12/7/r77mfas7zqfpqdf3azr6xtx_n4qa4c9)
217. STAFFORD P. : Psychedelics Encyclopedia, USA, Berkeley, Ronin Publishing Inc, 1978 / 1992.

218. STOKKINK P. : Psychedelics as a practice of truth, A Foucault argument, Chapter 10, in J. H. Ellens & T. B. Roberts (Eds.), « *The psychedelic policy quagmire : Law, health, freedom, and culture* » (pp. 177-202). Santa Barbara, CA: Praeger/ABC-CLIO, 2015.
219. STOLAROFF M.J. : Thanatos To Eros, 35 Years of Psychedelic Exploration, 1994, Reprinted by MAPS.org.  
[www.maps.org/t2e/toc.html](http://www.maps.org/t2e/toc.html)
220. STRAUSS N., BRIGHT S.J., WILLIAMS M.L. : Australia should be initiating a psychedelic research program : what are the barriers ? *Australian & New Zealand Journal of Psychiatry*, 2016, 50, 1036-1037.
221. STRASSMAN R.J. : Adverse reactions to psychedelic drugs : a review of the literature, *Journal of Nervous and Mental Diseases*, 1982, 172, (10), 577-595.
222. STRASSMAN R.J. : Human hallucinogenic drug research in the United States: a present-day case history and review of the process, *Journal of Psychoactive Drugs*, 1991, 23, (1), 29-38
223. STRASSMAN R.J. : DMT research : latest findings, *Newsletter of the MAPS*, 1993, 4, (2).
224. STRASSMAN R.J., CLIFFORD R., EBERHARD H. : N-N- Dimethyltryptamine in humans, *Psychedelic Illuminations*, 1994, 6, 68-71.
225. STRASSMAN R.J. : Human Hallucinogenic Drug Research : Regulatory, Clinical, and Scientific Issues, in « *Hallucinogens : An Update* », Editors : Geraline C. Lin, Ph.D., National Institute on Drug Abuse, Richard A. Glennon, Ph.D., Virginia Commonwealth University, *NIDA Research Monograph*, 1994, 146, 92-123.  
<https://archives.drugabuse.gov/sites/default/files/monograph146.pdf>
226. STRASSMAN R.J. : Hallucinogenic drugs in psychiatric research and treatment. Perspectives and prospects, *Journal of Nervous and Mental Disease*, 1995, 183, (3), 127-138.
227. STRASSMAN R.J., QUALLS C.R., BERG L.M. : Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans, *Biological Psychiatry*, 1996, 39, (9):784-95.
228. STRASSMAN R.J. : Perspectives on DMT research, *Bulletin of the MAPS*, 1998, 8, (3), 4-11.
229. STRASSMAN R.J. : Biomedical Research with Psychedelics : Current Models and Future Prospects (Chapter 12), in Forte Robert (editor) « *Entheogens and the Future of Religion* », Council on Spiritual Practice, San Francisco, 1997.  
(Republication forthcoming in 2012 by Inner Traditions, Rochester, VT.)
230. STRASSMAN R.J. : DMT : The Spirit Molecule, Rochester, Vermont, Park Street Press, 2001, trad. Française : DMT. La molécule de l'esprit, Paris, Editions Exergue, 2005.
231. STUDERUS E., GAMMA A., VOLLENWEIDER F.X. : Psychometric evaluation of the altered states of consciousness rating scale (OAV), *PLoS ONE*, 2010, 5:e12412.  
doi: 10.1371/journal.pone.0012412 .
232. SUEUR C. et al. Les substances hallucinogènes et leurs usages thérapeutiques, Revue de la littérature, partie 1, 1999, et partie 2, 2000, *Revue Toxibase*  
[http://www.cirddalsace.fr/docs/revue\\_toxibase/pdf/dossier\\_halluci.pdf](http://www.cirddalsace.fr/docs/revue_toxibase/pdf/dossier_halluci.pdf)  
[http://www.cirddalsace.fr/docs/revue\\_toxibase/pdf/dossier\\_halluc2.pdf](http://www.cirddalsace.fr/docs/revue_toxibase/pdf/dossier_halluc2.pdf)

233. SUEUR C., CAMMAS R., LEBEAU B. : L'Ecstasy au sein de la famille des substances psychédéliques : effets et dangerosité, *Psychotropes. Revue internationale des toxicomanies*, 2000, 6, (2), 9-71.
234. SUEUR C., INGOLD F. R. : Ecstasy, science et intoxication politique, *Les Cahiers de Prospective Jeunesse (Bruxelles)*, 2000, 5(1-2).  
[www.prospective-jeunesse.be/cahiers/cahier14-15/cahier14-15\\_art1.html](http://www.prospective-jeunesse.be/cahiers/cahier14-15/cahier14-15_art1.html)  
et SWAPS, 2000, 17, [www.pistes.fr/swaps/17\\_158.htm](http://www.pistes.fr/swaps/17_158.htm)
235. SUEUR C. : Trip, speed and Taz, *Psychotropes*, 2004, 10, (1), 61-97.  
<https://www.cairn.info/revue-psychotropes-2004-1-page-61.htm>
236. SUEUR C. : La recherche sur les capacités thérapeutiques des « substances hallucinogènes », *Chimères*, 2017, 91, 121-138.
237. SUEUR C. : Etat des lieux de la recherche sur les capacités thérapeutiques des « substances hallucinogènes » au 21<sup>e</sup> siècle, *Psychotropes*, 2017, 24, (3-4), 125-163.
238. SWANSON L.R. : Unifying Theories of Psychedelic Drug Effects, *Frontiers in Pharmacology*, 2018, 23 pp.  
Doi : 10.3389/fphar.2018.00172
239. TAGLIAZUCCHI E., CARHART-HARRIS R.L., LEECH R., NUTT D., CHIALVO D.R. : Enhanced repertoire of brain dynamical states during the psychedelic experience. *Human Brain Mapping*, 2014, 35, 5442-5456.  
Doi : 10.1002/hbm.22562
240. TASSIN J. P. : Hypothèses neurobiologiques des hallucinations, *Séminaire de Psychiatrie Biologique*, Editions Fournier Frères – Pharmuka, 1992, 21, 73-89.
241. TOSCANO A. : Étude auto-expérimentale avec deux drogues psychodysleptiques LSD 25 et psilocybine : comparaison des résultats, Mémoire de Psychiatrie, 1959, Paris.
242. VALLA J.P. : L'expérience hallucinogène, Masson, Paris, 1983.
243. VOLLENWEIDER F. X., GAMMA A., LIECHTI M., HUBER T. : Is a single dose of MDMA harmless? *Neuropsychopharmacology*, 1990, 21, 4, 598-600.
244. VOLLENWEIDER F. X., LEENDERS, K. L., SCHARFETTER C. et al. : Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using emission tomography (PET) and [18 F] fluorodeoxyglucose (FDG), *European Neuropsychopharmacology*, 1997, 7, sept-24.
245. VOLLENWEIDER F. X., LEENDERS K. L., SCHARFETTER C., MAGUIRE P., STADELmann O., ANGST J. : Positron emission tomography and fluorodesoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis, *Neuropsychopharmacology*, 1997, 16, 357-372.
246. VOLLENWEIDER F.X., VOLLENWEIDER-SCHERPENHUYZEN M.F., BABLER A. et al. : Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action, *Neuroreport*, 1998, 9, 17, 3897-3902.
247. VOLLENWEIDER F. X. : Recent advances and concepts in the search for biological correlates of hallucinogen-induced altered states of consciousness, *The Heffter Review of Psychedelic Research*, 1998, 1, 21-32.
248. VOLLENWEIDER F. X., GAMMA A., LIECHTI M., HUBER T. : Psychological and cardiovascular effects and short-term sequelae of MDMA (Ecstasy) in MDMA-naïve healthy volunteers, *Neuropsychopharmacology*, 1998, 19(4), 241-251.
249. VOLLENWEIDER F. X., KOMETER M. : The neurobiology of psychedelic drugs : implications for the treatment of mood disorders, *Nature Reviews Neuroscience*, 2010, 11, 9, 645-651.

250. WEBER E.T., ANDRADE R. : Htr2a gene and 5-HT(2A) receptor expression in the cerebral cortex studied using genetically modified mice, *Frontiers in Neuroscience*, 2010, 4, 36.
251. WEBSTER P. : Mixing the Kykeon, *ELEUSIS : Journal of Psychoactive Plants and Compounds*, New Series 4, 2000.  
[https://www.researchgate.net/publication/317412224 Mixing the Kykeon](https://www.researchgate.net/publication/317412224_Mixing_the_Kykeon)
252. WEBSTER P. : Augmenting Science with Psychedelics, Chapter 5, Manuscript, 2018, 20 p.
253. WESTKAEMPER R.B., GLENNON R.A. : Molecular Modeling of the Interaction of LSD and Other Hallucinogens with 5-HT2 Receptors, in « *Hallucinogens : An Update* », Editors : Geraldine C. Lin, Ph.D., National Institute on Drug Abuse, Richard A. Glennon, Ph.D., Virginia Commonwealth University, *NIDA Research Monograph*, 1994, 146, 263-283.  
<https://archives.drugabuse.gov/sites/default/files/monograph146.pdf>
254. WINTER J.C., HELSLEY S., FIORELLA D., RABIN R.A. : The acute effects of monoamine reuptake inhibitors on the stimulus effects of hallucinogens, *Pharmacology Biochemistry and Behavior*, 1999, 63, (3), 507-713.  
 PMID: 10418794
255. WOOD J., KIM Y., MOGHADDAM B. : Disruption of prefrontal cortex large scale neuronal activity by different classes of psychotomimetic drugs, *Journal of Neuroscience*, 2012, 32, 9, 3022-3031.
256. WYATT R.J., CANNON E.H., STOFF D.M., GILLIN J.C. : Interactions of hallucinogens at the clinical level, *Annals of New York Academy of Science*, 1976, 281, 456-486.

[\(1994\)](https://archives.drugabuse.gov/sites/default/files/monograph146.pdf)

## Substances psychédéliques et «psychologie» :

1. AIXALA M., ONA G., PARES O., BOUSO J.C. : Patterns of use, desired effects, and mental health status of a sample of natural psychoactive drug users, *Drugs : Education, Prevention and Policy*, 20191-8.  
Doi : 10.1080/09687637.2019.1611739
2. ALNAES R. : Therapeutic application of the change in consciousness produced by psycholytica (LSD, Psilocybin, etc.), *Acta Psychiatrica Scandinavica*, 1964, 39, (S180), 397–409.
3. ARGENTO E., STRATHDEE S. A., TUPPER K., BRASCHEL M., WOOD E., SHANNON K. : Does psychedelic drug use reduce risk of suicidality ? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting, 2017, *BMJ Open*, 7:e016025.  
Doi : 10.1136/bmjopen-2017-016025
4. ARGENTO E., BRASCHEL M., WALSH Z., SOCIAS M.E., SHANNON K. : The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women, *Journal of Psychopharmacology*, 2018, 1-7.  
Doi : 10.1177/0269881118798610
5. ARGENTO E., TUPPER K.W., SOCIAS M.E. : The tripping point : The potential role of psychedelic-assisted therapy in the response to the opioid crisis, *International Journal of Drug Policy*, 2019, 2 p.  
Doi : 10.1016/j.drugpo.2018.11.006
6. BAGGOTT M.J. : Psychedelics and creativity : A review of the quantitative literature (No. e1468). San Diego, CA, PeerJ PrePrints, 2015.
7. BARRETT F.S., ROBBINS H., SMOOKE D., BROWN J.L., GRIFFITHS R.R. : Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions, *Frontiers in Psychology*, 2017, 8, 1238.
8. BARRETT F.S., PRELLER K.H., KAELEN M. : Psychedelics and music : neuroscience and therapeutic implications, *International Review of Psychiatry*, 2018, 1-13.  
Doi : 10.1080/09540261.2018.1484342
9. BOUSO J.C., Dos SANTOS R.G., ALCAZAR-CORCOLES M.A., HALLAK, J.E.C. : Serotonergic psychedelics and personality: A systematic review of contemporary research, *Neuroscience and Biobehavioral Reviews*, 2018, 87, 118–132.
10. BREAKY W. et al. : Hallucinogenic Drugs as Precipitants of Schizophrenia, *Psychological Medicine*, 1974, 4, (3), 255-261.
11. CARDEÑA E., WINKELMAN M. (Eds.) : Altering consciousness : Multidisciplinary perspectives, Santa Barbara, CA, Praeger ABC-CLIO, 2011.
12. DEVENOT N. : Psychedelics & Intersectionality : Gender, Ecology, Race, and Sexuality. A critical Bibliography, Postdoctoral fellow, Department of English, University of Puget Sound, in "Psychedelic Drugs", *Macmillan Interdisciplinary Handbook : Gender*, 2016, Vol 7.
13. DOBLIN R. : Pahnke's « Good Friday experiment » : a long-term follow-up and methodological critique, *The Journal of Transpersonal Psychology*, 1991, 23, (1).
14. DORSEN C., PALAMAR J., SHEDLIN M.G. : Ceremonial « Plant Medicine » use and its relationship to recreational drug use : an exploratory study, *Addiction Research and Theory*, 2018, 8 p.  
Doi : 10.1080/16066359.2018.1455187

15. FADIMAN J. : Enhanced Problem Solving in Focused Sessions. Part 3 in *The Psychedelic Explorer's Guide : Safe, Therapeutic, and Sacred Journeys*, Park Street Press, Rochester, VT, 2011.
16. FADIMAN J. : Behavioral Changes after Psychedelic Therapy. A Questionnaire Study of Psychedelic Experiences, Chapters 21 and 22, in *The Psychedelic Explorer's Guide : Safe, Therapeutic, and Sacred Journeys*, Park Street Press, Rochester, VT, 2011.
17. FANTEGROSSI W.E., MURNANE K.S., REISSIG C.J. : The behavioral pharmacology of hallucinogens, *Biochemistry and Pharmacology*, 2008, 75, (1), 17-33.
18. FORSTMANN M, SAGIOGLOU C. : Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness. *Journal of Psychopharmacology*, 2017, 31, (8), 975–988.
19. FRIEDMAN H. : The renewal of psychedelic research : implications for humanistic and transpersonnal psychology, *The Humanistic Psychologist*, 2006, 34, (1), 39-58.
20. GIRN M., CHRISTOFF K. : Expanding the Scientific Study of Self-Experience with Psychedelics, *Journal of Consciousness Studies*, 2018, 25, (11-12), 131-154.
21. GROB C.S. : Psychiatric research with hallucinogens : What have we learned ?, *Yearbook for Ethnomedicine and the Study of Consciousness*, 1994, 3.
22. HARMAN W.W., MCKIM R.H., MOGAR R.E., FADIMAN J., STOLAROFF M.J. : Psychedelic agents in creative problem-solving : A pilot study, *Psychological Reports*, 1966, 19, (1), 211-227.
23. HENDRICKS P.S., CLARK C.B., JOHNSON M.W., FONTAINE K.R., CROPSEY K. L. : Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision, *Journal of Psychopharmacology*, 2014, 28, (1), 62-66.
24. HENDRICKS P.S., THORNE C.B., CLARK C.B., COOMBS D.W., JOHNSON M.W. : Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population, *Journal of Psychopharmacology*, 2015, 29, (3), 280–288.
25. HENDRICKS P.S., CRAWFORD M.S., CROPSEY K.L., COPES H., SWEAT N.W., WALSH Z., PAVELA G. : The relationships of classic psychedelic use with criminal behavior in the United States adult population, *Journal of Psychopharmacology*, 2018, 32, (1), 37-48.
26. JUNGABERLE H., THAL S., ZEUCH A., ROUGEMENT-BÜCKING A., von HEYDEN M., AICHER H., SCHEIDEGGER M. : Positive psychology in the investigation of psychedelics and entactogens : A critical review, *Neuropharmacology*, 2018.  
Doi : 10.1016/j.neuropharm.2018.06.034
27. KRAEHENMANN R. : Dreams and Psychedelics : Neurophenomenological Comparison and Therapeutic Implications, *Current Neuropharmacology*, 2017, 15, (7), 1032-1042.  
Doi : 10.2174/1573413713666170619092629
28. LIECHTI M.E., DODDER P.C., SCHMID Y. : Alterations of consciousness and mystical-type experiences after acute LSD in humans, *Psychopharmacology (Berl)*, 2017, 234, 1499–1510.  
Doi : 10.1007/s00213-016-4453-0
29. LUKE D. : Psychoactive Substances and Paranormal Phenomena : a Comprehensive Review, *International Journal of Transpersonnal Studies*, 2012, 31, (1), 97-156.

30. MASTERS R.E.L., HOUSTON J. : The Varieties of Psychedelic Experience, Dell Publishing, 1966, 240 p
31. NOUR M.M., EVANS L., NUTT D., CARHART-HARRIS R. L. : Ego-dissolution and psychedelics : validation of the Ego-Dissolution Inventory (EDI), *Frontiers in Human Neurosciences*, 2016, 10, 269.  
doi: 10.3389/fnhum.2016.00269
32. PRELLER K.H., VOLLENWEIDER F.X. : Modulation of Social Cognition via Hallucinogens and « Entactogens », *Frontiers in Psychiatry*, 2019, 10, Article 881.  
Doi : 10.3389/fpsyg.2019.00881
33. SAYIN H.U. : A Comparative Review of the Neuro-Psychopharmacology of Hallucinogen-Induced Altered States of Consciousness : The Uniqueness of Some Hallucinogens, *NeuroQuantology*, 2012, 10, (2), 316-340.
34. SAYIN H.U. : A Comparative Review of Psychopharmacology of Hallucinogen-Induced Altered States of Consciousness : Relation to Sexuality, *Sexus Journal*, 2018, 03, (07), 413-450.  
[www.sexusjournal.com](http://www.sexusjournal.com)
35. STANSBURY K.A. : The Influence of Psychedelic Induced Ego-Dissolution on Self-Compassion, *Thesis, School of Social Work*, California State University, Long Beach, May 2019, 64 p.
36. STANTON M., BARDONI A. : Drug Flashbacks : Reported frequency in a military population, *American Journal of Psychiatry*, 1972, 129, (6), 751-755.
37. SZABO A., HORWATH L., SZUMMER C. : Phenomenology and Altered States of Consciousness : A New Framework for Analysis, *Psychologia Hungarica*, 2014, II, (2), 7-29.  
Doi : 10.12663/PSYHUNG.2.2014.2.1
38. VOLLENWEIDER F.X., KOMETER M. : The neurobiology of psychedelic drugs: implications for the treatment of mood disorders, *Nature Reviews Neuroscience*, 2010, 11, (9), 642-651.  
Doi : 10.1038/nrn2884
39. WEBSTER P. : Heaven and Hell revisited, *The Psychedelic Library*, 1996.
40. WEBSTER P. : Augmenting Science with Psychedelics, Chapter 5, Manuscript, 2018, 20 p.
41. WEBSTER P. : Psychedelic Elephant, July 2019.  
[www.rechearchgate.net/publications/334808255](http://www.rechearchgate.net/publications/334808255)
42. WINKELMAN M., ROBERTS T.B. (editors) : Part I : Treating Substance Abuse, In Vol. 2 of « *Psychedelic Medicine: New Evidence for Hallucinogenic Substances as Treatments* », Praeger, Westport, CT./Greenwood, London. (Six chapters by John H. Halpern, Richard Yensen and Donna Dryer, Joseph D. Calabrese, Kenneth R. Alper and Howard S. Lotsof, Evgeny Krupitsky and Eli Kolp, and Jacques Mabit. The treatments include ayahuasca, peyote, LSD, ketamine, and ibogaine.), 2007.
43. WINKELMAN M.J. : The Mechanism of Psychedelic Visionary Experiences : Hypotheses from Evolutionary Psychology, *Frontiers in Neuroscience*, 2017, 17 p.  
Doi : 10.3389/fnins.2017.00539
44. WINKELMAN M.J. : An ontology of psychedelic entity experiences in evolutionary psychology and neurophenomenology, *Journal of Psychedelic Studies*, 2018.  
Doi : 10.1556/2054.2018.002
45. ZAMBERLAN F., SANZ C., MARTINEZ VIVOT R., PALLAVICINI, FIRE EROWID, EARTH EROWID, TAGLIAZUCCHI E. : The Varieties of the Psychedelic Experience: A Preliminary Study of the Association Between the Reported Subjective Effects

and the Binding Affinity Profiles of Substituted Phenethylamines and Tryptamines, *Frontiers in Integrative Neuroscience*, 2018.  
Doi : 10.3389/fnint.2018.00054